Want to join the conversation?
$LH 2Q15 Call: The integration of our businesses continues to go well. I am enthusiastic about efforts of our sales force & scientific leadership teams. We’ve dedicated teams focused on driving more than $300MM in incremental annual revenue by 2018 through accelerated clinical trial enrollment and end-to-end capabilities in companion diagnostics.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.